A targeted radiotherapy solution for hepatic and systemic cancer, delivering a potent alpha emitter directly to the tumor

Node Pharma has developed a novel targeted radiotherapy that enables the pre-selection and treatment of liver cancer patients. Primary liver cancer is ranked as the sixth most frequently occurring, and as the third most deadly cancer type as of 2022 (Globocan). Furthermore, liver cancer is frequently diagnosed synchronously with a range of other primary cancers, as pancreas, breast melanoma and colorectal cancer. Current therapies have limited effect, and often present severe side effects, and there are limited treatment possibilities for advanced-stage patients. Node Pharma’s solution is based on nanoparticles capable of delivering radioisotopes to primary and secondary liver cancer. Our initial pre-clinical efficacy and safety results demonstrate that our technology can efficiently clear tumor with no observed side effects. Node targeted radiotherapy has the potential to offer a solution to a substantial patient cohort with no good treatment options. The next step is to continue our developmental roadmap and perform an initial clinical validation. Node Pharma will lead this EIC-A project which will consist of continuing the pre-clinical activities under stringent standards and conducting a phase I clinical trial to assess the safety of our solution. The EIC support will create a solid base for the growth of our company as it will unlock a critical funding step in our innovation roadmap and will also be a stepping stone on the EU path in this market.